Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2011 - 2026)
Lineage Cell Therapeutics (LCTX) posted quarterly Return on Capital Employed of 36.64% for Q1 2026, down 1519.0% year-over-year from 2.58% in Q1 2025, and up 10.2% quarter-over-quarter from 40.8% in Q4 2025.
Lineage Cell Therapeutics (LCTX) Return on Capital Employed (2011 - 2026) Analysis & Trends
Lineage Cell Therapeutics' Return on Capital Employed history runs 16 years deep, the most recent figure standing at 36.64% for Q1 2026.
- In Q1 2026, Return on Capital Employed fell 1519.0% year-over-year to 36.64%; the TTM figure through Mar 2026 stood at 36.64% (down 1519.0% YoY), while the FY2025 annual figure was 36.07%, down 1301.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 36.64%, up from 40.8% in the prior quarter.
- The five-year high for Return on Capital Employed was 20.77% in Q4 2022, with the low at 43.52% in Q3 2025.
- The 5-year median for Return on Capital Employed is 28.32% (2024), against an average of 30.99%.
- Peak annual rise in Return on Capital Employed reached 2576 bps in 2022, while the deepest fall reached 1824 bps in 2022.
- Lineage Cell Therapeutics' Return on Capital Employed stood at 20.77% in 2022, then plunged by 39 bps to 28.88% in 2023, then rose by 18 bps to 23.62% in 2024, then plunged by 73 bps to 40.8% in 2025, then rose by 10 bps to 36.64% in 2026.
- Business Quant data shows LCTX's Return on Capital Employed at 36.64% in Q1 2026, 40.8% in Q4 2025, and 43.52% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.76% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.74% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -55.45% |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 13.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.20% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 7.88% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 26.09% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -50.93% |
| 10 | Lineage Cell Therapeutics | 270.61 Mn | 212.77 Mn | 1.07 Mn | -26.89% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -26.89% |
| Mar 31, 2026 | -36.64% |
| Dec 31, 2025 | -40.80% |
| Sep 30, 2025 | -43.52% |
| Jun 30, 2025 | -38.93% |
| Mar 31, 2025 | -21.45% |
| Dec 31, 2024 | -23.62% |
| Sep 30, 2024 | -26.48% |
| Jun 30, 2024 | -28.32% |
| Mar 31, 2024 | -28.17% |
| Dec 31, 2023 | -28.88% |
| Sep 30, 2023 | -26.88% |
| Jun 30, 2023 | -24.44% |
| Mar 31, 2023 | -22.49% |
| Dec 31, 2022 | -20.77% |
| Sep 30, 2022 | -39.82% |
| Jun 30, 2022 | -39.70% |
| Mar 31, 2022 | -35.98% |
| Dec 31, 2021 | -46.53% |
| Sep 30, 2021 | -21.62% |